Detalhe da pesquisa
1.
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.
Nat Immunol
; 20(7): 835-851, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31160797
2.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38507751
3.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35263519
4.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34914339
5.
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin
; 67(4): 290-303, 2017 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28294295
6.
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 24(2): 162-174, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36623515
7.
Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.
J Biol Chem
; 298(4): 101817, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35278434
8.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Artigo
Inglês
| MEDLINE | ID: mdl-31825569
9.
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
J Natl Compr Canc Netw
; 21(11): 1172-1180.e3, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37935109
10.
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226).
Biomarkers
; 28(3): 313-322, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-36647745
11.
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
N Engl J Med
; 380(13): 1226-1234, 2019 03 28.
Artigo
Inglês
| MEDLINE | ID: mdl-30917258
12.
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
Breast Cancer Res Treat
; 193(2): 253-264, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35347549
13.
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.
Ann Surg Oncol
; 29(13): 8016-8023, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-35900648
14.
Inflammatory breast cancer: early recognition and diagnosis is critical.
Am J Obstet Gynecol
; 225(4): 392-396, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33845027
15.
Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).
Support Care Cancer
; 29(5): 2509-2517, 2021 May.
Artigo
Inglês
| MEDLINE | ID: mdl-32929540
16.
Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.
Oncologist
; 25(9): 749-757, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32431013
17.
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Breast Cancer Res
; 21(1): 78, 2019 07 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31277699
18.
Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing.
Oncologist
; 24(2): 178-184, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30297386
19.
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Oncologist
; 24(7): 893-900, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30679318
20.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artigo
Inglês
| MEDLINE | ID: mdl-27717303